The Association of Haptoglobin Genotype with the Development of Liver Disease and a Strategy for Personalized Treatment of NASH
Background Haptoglobin is a binding protein that scavenges free hemoglobin and is highly expressed in the liver. The human haptoglobin gene (HP) is polymorphic, consisting of two alleles, HP1 and HP2. Recent studies have found that haptoglobin variants are strongly associated with cholesterol levels, as haptoglobin is capable of binding apolipoprotein E and regulating HDL function3-4. Together, these functions allow haptoglobin to play a significant role in the transport of cholesterol from tissues to the liver. Goal Study the association of haptoglobin genotypes with the development of nonalcoholic steatohepatitis (NASH) using 2000 NASH CRN patient DNA samples. Methods Allelic differences were determined using TaqMan genotyping PCR and were analyzed on an ABI7300 real-time PCR machine. Following allele identification, the association between genotype and phenotype was determined, with focus on NASH scores and other relevant measurements. Results The distribution of haptoglobin genotype frequencies were 46% HP1/HP2, 39% HP2/HP2, and 15% HP1/HP1, with no gender differences. The results suggest that HP2/HP2 is associated with specific liver disease states such as an NAFLD score of 6, fibrosis in zone 2 of the liver and periportal area, and a steatosis grade of 34-66%. The most abundant genotype observed was heterozygous for several ethnic groups, as expected. However, patients of Asian ancestry demonstrated homozygous HP2 as the majority genotype. Conclusion HP genotype plays an important role in liver disease development. Genotyping distribution differences in ethnic groups may inform personalized treatment strategies, such as recommending Vitamin E for patients homozygous for HP21 2.
1.Zang, S.; Chen, J.; Song, Y.; Bai, L.; Chen, J.; Chi, X.; He, F.; Sheng, H.; Wang, J.; Xie, S.; Xie, W.; Yang, Y.; Zhang, J.; Zheng, M.; Zou, Z.; Wang, B.; Shi, J.; Chinese, N. C. R. N., Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. Adv Ther 2018, 35 (2), 218-231.
2.Boettger, L. M.; Salem, R. M.; Handsaker, R. E.; Peloso, G. M.; Kathiresan, S.; Hirschhorn, J. N.; McCarroll, S. A., Recurring exon deletions in the HP (haptoglobin) gene contribute to lower blood cholesterol levels. Nat Genet 2016, 48 (4), 359-66.
3.Spagnuolo, M. S.; Maresca, B.; La Marca, V.; Carrizzo, A.; Veronesi, C.; Cupidi, C.; Piccoli, T.; Maletta, R. G.; Bruni, A. C.; Abrescia, P.; Cigliano, L., Haptoglobin interacts with apolipoprotein E and beta-amyloid and influences their crosstalk. ACS Chem Neurosci 2014, 5 (9), 837-47.
4.Costacou, T.; Levy, A. P.; Miller, R. G.; Snell-Bergeon, J.; Asleh, R.; Farbstein, D.; Fickley, C. E.; Pambianco, G.; de la Vega, R.; Evans, R. W.; Orchard, T. J., Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial. Acta Diabetol 2016, 53 (2), 243-50.
Copyright (c) 2018 Nicole Shammas, Tiebing Liang, PhD
This work is licensed under a Creative Commons Attribution 4.0 International License.